Publications by authors named "Manuel Sequeira"

Claim this Profile
C
Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors.
Cheryl A London, Jaime Acquaviva, Donald L Smith, Manuel Sequeira, Luisa Shin Ogawa

Clin Cancer Res· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.
David A Proia, Donald L Smith, Junyi Zhang, John-Paul Jimenez, Jim Sang, Manuel Sequeira

Mol Cancer Ther· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
Donald L Smith, Jaime Acquaviva, Manuel Sequeira, John-Paul Jimenez, Chaohua Zhang

Target Oncol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.
Suqin He, Donald L Smith, Manuel Sequeira, Jim Sang, Richard C Bates

Invest New Drugs· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.
Jaime Acquaviva, Suqin He, Chaohua Zhang, John-Paul Jimenez, Masazumi Nagai, Manuel Sequeira

Mol Cancer Res· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
Jaime Acquaviva, Suqin He, Jim Sang, Donald L Smith, Manuel Sequeira

Mol Cancer Res· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Jaime Acquaviva, Donald L Smith, John-Paul Jimenez, Chaohua Zhang, Manuel Sequeira

Mol Cancer Ther· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
David A Proia, Chaohua Zhang, Manuel Sequeira, John-Paul Jimenez, Suqin He

Clin Cancer Res· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.
Jim Sang, Jaime Acquaviva, Julie C Friedland, Donald L Smith, Manuel Sequeira

Cancer Discov· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
Suqin He, Chaohua Zhang, Ayesha A Shafi, Manuel Sequeira, Jaime Acquaviva

Int J Oncol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.
David A Proia, Jim Sang, Suqin He, Donald L Smith, Manuel Sequeira

Invest New Drugs· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.
Jaime Acquaviva, Donald L Smith, Jim Sang, Julie C Friedland, Suqin He, Manuel Sequeira

Mol Cancer Ther· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis